Definitive Contract 75A50124C00003
Award Date
3/20/24
Potential Completion Date
12/31/32
Potential Value
$38M
Awardee
Mapp Biopharmaceutical, Inc.
Ultimate Awardee
Not listed
PSC Category
AJ11 - General Science And Technology R&D Services; General Science And Technology; Basic Research
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $906,651,397.58 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Mapp Biopharmaceutical, Inc., a for-profit biotechnology company based in San Diego, California. The contract is for the procurement of therapeutics for Ebola, Sudan, and Marburg viruses, with a period of performance running through September 29, 2032. This contract has no set-aside designation. Mapp Biopharmaceutical is...
This is a federal contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in the development of antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, valued at $6,173,324.00, is for research and development services during the base period, with a period of performance ending on August 31, 2017. The contract is a Cost Plus Fixed Fee Definitive...
This is a cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc. for the development of Mapp's therapeutic intervention MBP091 as an immunotherapy for the treatment of Marburg virus infection. The contract has a ceiling value of $299,045,139.03 and a completion date of July 31, 2036. No set-aside was used for this award. Mapp Biopharmaceutical is a biotechnology company that specializes in developing...
This is a Definitive Contract awarded to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California, by the Defense Health Agency, a component of the U.S. Department of Defense. The contract has a ceiling value of $1,192,803.19 and is for the BASE YEAR of the MACV Contract, which generates MACV IGG2. The contract is a Firm Fixed Price arrangement with a period of performance through March 1, 2025. There was no set-aside designation for this award. Mapp Biopharmaceutical...
This is a $30,559,760.00 cost-plus-fixed-fee delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The contract is for the development of the MAPP biopharmaceutical Viral Hemorrhagic Fever (VHF) Medical Countermeasure (MCM) platform. This work is being performed under the Centers for Innovation in...
This is a $159,990,035.88 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Ridgeback Biotherapeutics LP, a for-profit woman-owned business, for the development and treatment of Ebola using the monoclonal antibody mAb114. The contract has an ultimate completion date of July 31, 2023. This sole-source contract was awarded on March 19, 2020 without a set-aside based on Ridgeback...
This is a $228,598,975.00 cost-sharing definitive contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Janssen Research & Development, LLC on September 21, 2018. The contract is for the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats, in support of the Public Health Emergency Medical Countermeasures...
Mapp Biopharmaceutical, Inc. has been awarded a definitive cost-plus-fixed-fee contract valued at $1.5 million by the U.S. Army's Research, Development and Engineering Command (RDECOM) to continue research under the Small Business Technology Transfer (STTR) Phase II program. The contract is for continued research and development originally solicited through the STTR mechanism. Performance will take place in San Diego, California over a period of thirty-three months concluding in February 2023....
This is a $111,268,952.26 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Merck Sharp & Dohme LLC (doing business as Merck), a for-profit pharmaceutical manufacturer. The contract is for the manufacturing and development of the RVSV-ZEBOV vaccine, a critical medical countermeasure. It does not have a set-aside designation. Merck also holds several significant indefinite delivery vehicles...
This federal contract award, valued at $330,136,246.14, was granted by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to 4J Therapeutics Inc., a self-certified small disadvantaged business. The contract's objective is to demonstrate the versatility and efficacy of 4J Therapeutics' programmable antiviral technology platform by assembling a preclinical package for LNA14, performing a Phase 1a...